Exploring the illegal drug issue in international context, this book looks at why harmonization has not already taken place at the European level. It considers the desirability and viability of harmonization, examines the conflict between repressive and liberal drug policies and applies a multi-level governance lens to the issue.

Martin Elvins' book is the first to trace the evolution of anti-drugs policies at European Union level from the late 1960s to the present. Phases of drug policy development, key policy actors and institutions are described with particular reference to the influence of transnational networks of expertise. Policy development is placed in the context of both European integration and a broad harmonization of international policies against drug trafficking. Concerns are also raised about secretive and anti-democratic features on intergovernmental EU decision-making.

While there may be consensus on the broader issues of the core objectives of the health care system, expectations differ between EU countries, and European national policy-makers. This book seeks firstly to assess the impact of the enlargement process and then to analyse the challenges that lie ahead in the field of health and health policy.

Analysing arguably one of the most controversial areas in public policy, this pioneering Research Handbook brings together contributions from expert researchers to provide a global overview of the shifting dynamics of drug policy. Emphasising connections between the domestic and the international, contributors illustrate the intersections between drug policy, human rights obligations and the 2030 Sustainable Development Agenda, offering an insightful analysis of the regional dynamics of drug control and the contemporary and emerging problems it is facing.

The drug control regime established by the international community has not succeeded in curbing either the demand for, or the offer of, narcotics. But, despite a series of developments in the Americas – including the legalisation of cannabis in Uruguay and in several states in the United States of America – there is still little support in Europe for repealing drug-prohibition laws. Nevertheless, a gradual policy convergence reveals the emergence of a European model favouring public-health strategies over a strictly penal approach to combatting drugs, while growing transnational support for legalisation indicates the persistence of an alternative paradigm for drug policy. This book examines the various influences on drug policies in Europe, as grassroots movements, NGO networks, private foundations and academic research centres increasingly confront the prevailing discourses of drug prohibition. Pursuing an interdisciplinary approach and bringing together legal scholars, social scientists and practitioners, it provides a comprehensive and critical assessment of drug policy reform in Europe.

Medical devices that are deemed to have a moderate risk to patients generally cannot go on the market until they are cleared through the FDA 510(k) process. In recent years, individuals and organizations have expressed concern that the 510(k) process is neither making safe and effective devices available to patients nor promoting innovation in the medical-device industry. Several high-profile mass-media reports and consumer-protection groups have profiled recognized or potential problems with medical devices cleared through the 510(k) clearance process. The medical-device industry and some patients have asserted that the process has become too burdensome and is delaying or stalling the entry of important new medical devices to the market. At the request of the FDA, the Institute of Medicine (IOM) examined the 510(k) process. Medical Devices and the Public's Health examines the current 510(k) clearance process and whether it optimally protects patients and promotes innovation in support of public health. It also identifies legislative, regulatory, or administrative changes that will achieve the goals of the 510(k) clearance process. Medical Devices and the Public's Health recommends that the U.S. Food and Drug Administration gather the information needed to develop a new regulatory framework to replace the 35-year-old 510(k) clearance process for medical devices. According to the report, the FDA's finite resources are best invested in developing an integrated premarket and postmarket regulatory framework.

This book examines the topical issue of global drug policy and outlines five steps that could be taken to improve its effectiveness. A public criminology approach is applied to explore not only what could be done, but also why it matters and how it could be achieved. It argues that more effective global drug policies require an acknowledgement of the failure of a war on drugs approach and the harms it has caused. Instead, strategies that reduce drug related harm should be prioritised. An innovative and diverse range of approaches should be developed that are underpinned by evaluation and dissemination of results. Finally, the horizons of the drug policy debate should be broadened. In line with the central aims of public criminology, this book provides an accessible contribution to global drug policy debates that links theory and practice and which will have appeal to a wide range of audiences.